Complete Posterior Vitreous Detachment Reduces the Need for Treatment of Diabetic Macular Edema.
Journal
Ophthalmic surgery, lasers & imaging retina
ISSN: 2325-8179
Titre abrégé: Ophthalmic Surg Lasers Imaging Retina
Pays: United States
ID NLM: 101599215
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
received:
16
09
2018
accepted:
22
03
2019
entrez:
23
11
2019
pubmed:
23
11
2019
medline:
11
2
2020
Statut:
ppublish
Résumé
To evaluate the vitreomacular interface and its relation to treatment burden for diabetic macular edema (DME) in patients without overt vitreomacular traction (VMT). A retrospective cohort study of 494 eyes from 274 patients who had macular spectral-domain optical coherence tomography (SD-OCT) and did not have proliferative diabetic retinopathy, DME, or VMT at the initial visit. Posterior vitreous detachment (PVD) was categorized at the initial visit into five stages (0-4) using SD-OCT parameters alone. Two of 34 eyes (6.9%) presenting with a complete PVD required DME treatment during follow-up, whereas 144 of 460 eyes (31.3%) without a complete PVD at baseline required treatment (P = .001, Chi-squared). After adjusting for age, ethnicity, gender, and HbA1c, complete PVD at baseline was associated with a significant reduction in risk of DME therapy (hazard ratio: 0.18; 95% confidence interval, 0.05-0.73; P = .02). Complete PVD is independently associated with a reduced need for DME treatment. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e266-e273.].
Sections du résumé
BACKGROUND AND OBJECTIVE
To evaluate the vitreomacular interface and its relation to treatment burden for diabetic macular edema (DME) in patients without overt vitreomacular traction (VMT).
PATIENTS AND METHODS
A retrospective cohort study of 494 eyes from 274 patients who had macular spectral-domain optical coherence tomography (SD-OCT) and did not have proliferative diabetic retinopathy, DME, or VMT at the initial visit. Posterior vitreous detachment (PVD) was categorized at the initial visit into five stages (0-4) using SD-OCT parameters alone.
RESULTS
Two of 34 eyes (6.9%) presenting with a complete PVD required DME treatment during follow-up, whereas 144 of 460 eyes (31.3%) without a complete PVD at baseline required treatment (P = .001, Chi-squared). After adjusting for age, ethnicity, gender, and HbA1c, complete PVD at baseline was associated with a significant reduction in risk of DME therapy (hazard ratio: 0.18; 95% confidence interval, 0.05-0.73; P = .02).
CONCLUSION
Complete PVD is independently associated with a reduced need for DME treatment. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e266-e273.].
Identifiants
pubmed: 31755977
doi: 10.3928/23258160-20191031-13
pmc: PMC7941753
mid: NIHMS1674848
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e266-e273Subventions
Organisme : NEI NIH HHS
ID : K08 EY025269
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007120
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY002687
Pays : United States
Informations de copyright
Copyright 2019, SLACK Incorporated.
Références
Int Ophthalmol. 2011 Feb;31(1):51-3
pubmed: 20857172
Am J Ophthalmol. 2005 May;139(5):807-13
pubmed: 15860284
Am J Ophthalmol. 2005 Apr;139(4):638-52
pubmed: 15808159
Ophthalmology. 1996 Feb;103(2):205-6
pubmed: 8594502
Retina. 2011 Jul-Aug;31(7):1400-4
pubmed: 21233785
Diabetes. 1995 Aug;44(8):968-83
pubmed: 7622004
JAMA Ophthalmol. 2013 Oct;131(10):1348-52
pubmed: 23974841
Int Ophthalmol. 2005 Feb-Apr;26(1-2):15-9
pubmed: 16779571
Curr Eye Res. 2015 Feb;40(2):234-46
pubmed: 25545999
Ophthalmology. 1990 Jul;97(7):889-91
pubmed: 2381702
PLoS One. 2014 Jul 18;9(7):e102950
pubmed: 25036044
Acta Ophthalmol. 2016 Jun;94(4):346-52
pubmed: 26547796
Ophthalmology. 2010 Jun;117(6):1087-1093.e3
pubmed: 20299105
Clin Ophthalmol. 2014;8:1-10
pubmed: 24376338
Am J Ophthalmol. 2010 Apr;149(4):641-50
pubmed: 20138610
Diabetologia. 2001 Feb;44(2):156-63
pubmed: 11270671
Ophthalmic Surg. 1990 Aug;21(8):544-9
pubmed: 2234801
Retina. 2017 Jul;37(7):1270-1276
pubmed: 27749693
Retina. 2017 Apr;37(4):749-752
pubmed: 27471829
J Ophthalmol. 2015;2015:392983
pubmed: 26425349
Trans Am Ophthalmol Soc. 2005;103:537-67
pubmed: 17057817
Am J Ophthalmol. 2005 Feb;139(2):302-10
pubmed: 15733992
Acta Ophthalmol. 2012 Jun;90(4):e264-8
pubmed: 22280486
Graefes Arch Clin Exp Ophthalmol. 2008 Mar;246(3):329-32
pubmed: 18228032
Jpn J Ophthalmol. 2012 May;56(3):262-7
pubmed: 22476626